A multicenter, double-blind, randomized parallel-group, study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes inadequately controlled on metformin 500 mg bid monotherapy.
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Vildagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2008 Status changed from recruiting to in progress. Updated from ClinicalTrials.gov.